The SELECT trial enrolled 17,604 adults with overweight and established cardiovascular disease. One registered primary endpoint: three-point MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). Hazard ratio 0.80, published in the New England Journal of Medicine in November 2023. The private longevity capital circulating in Singapore's family-office health portfolios is pricing the same compound as a biological-aging drug.

The mechanistic inference runs three steps: semaglutide reduces visceral adiposity; visceral adiposity sustains chronic IL-6 and CRP elevation; that inflammatory burden accelerates senescent cell accumulation and, by that route, compresses biological age. Each step is mechanistically defensible. None is supported by a Phase 2 randomized trial with a methylation-age clock (DunedinPACE, GrimAge, or PhenoAge) as the registered primary endpoint. ClinicalTrials.gov carries no such protocol as of June 2026. The capital is pricing the inference. The clinical record is pricing cardiovascular risk reduction in a specific high-MACE-risk population. TGA's Advisory Committee on Medicines approved high-dose semaglutide for chronic weight management on a weight-and-cardiovascular-risk indication; no variation of that registration names a biological-age endpoint.